Farydak
Drug - Farydak® (panobinostat) [Genentech, Inc.]
May 2016
Therapeutic area - Oncology
Approval criteria
- Patient must be 18 years of age or older AND
- Have a diagnosis of multiple myeloma AND
- Will be used in conjunction with bortezomib and dexamethasone AND
- Has received at least 2 prior chemotherapy regimens, including bortezomib and an immunomodulatory agent
Quantity limit
Maximum of 6 capsules per 21 days
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411
